Suzhou Zelgen Biopharmaceuticals (688266) Stock Overview

Suzhou Zelgen Biopharmaceuticals Co., Ltd. researches and develops, manufactures, and sells medicines in the People's Republic of China. It offers donafenib tablets; recombinant human thrombin for topincal use; jacktinib tablets; and recombinant human thyroid-stimulating hormone for injection; obeticholic acid magnesium tablets; ZG19018 tablets; ZG005 powder for injection; and alkotinib capsules for the treatment of liver cancer, non-small cell lung cancer, small cell lung cancer, colorectal cancer, thyroid cancer, and neuroendocrine cancer, as well as multiple therapeutic areas, such as bleeding, hepatobiliary diseases, and autoimmune diseases. The company was founded in 2009 and is based in Kunshan, the People's Republic of China.